Research
Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective
-
* Corresponding author: William J Valentine valentine@ossianconsulting.com
Cost Effectiveness and Resource Allocation 2009, 7:9 doi:10.1186/1478-7547-7-9
No comments have yet been made on this article.